mayo clinic tirzepatide researchers are investigating tirzepatide's effect on menopausal vasomotor symptoms & biological aging in obese women (ages Primary Care in Rochester and

Metallomics 9 (12), 17031734

So in summary, you can see why theres so much to be excited for with hCG/TRT

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial A 56-week trial with 793 participants (mean BMI 36.5) found that naltrexone SR (32 mg/day) plus bupropion SR (360 mg/day) combined with intensive behavior modification (BMOD) led to significantly greater weight loss and improved cardiometabolic markers compared to placebo with BMOD, though nausea was more common

We are here for you and ready to help, whether it is in-person or online

Replace daily

A recent review by Campbell [19] attempts to reconcile the paradoxical observations